Regulus Therapeutics
RGLS
$2.12
Share price
-4.73%
Change (1 day)
71.95%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - P/B ratio
P/B ratio as of April 2024 : 5.14
According to Regulus Therapeutics's latest financial reports the company has a price-to-book ratio of 5.14.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Regulus Therapeutics - P/B ratio (from 2012 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 0.9160 | 32.17% |
| 2022-12-31 | 0.6930 | -17.17% |
| 2021-12-31 | 0.8367 | -74.6% |
| 2020-12-31 | 3.29 | 252.45% |
| 2019-12-31 | 0.9346 | -166.67% |
| 2018-12-31 | -1.40 | -145.66% |
| 2017-12-31 | 3.07 | 44.57% |
| 2016-12-31 | 2.12 | -42.63% |
| 2015-12-31 | 3.70 | -37.76% |
| 2014-12-31 | 5.95 | 79.97% |
| 2013-12-31 | 3.30 | -9.11% |
| 2012-12-31 | 3.64 | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 1.38 | -73.20% | 🇫🇷 France |
 Biogen BIIB | 1.87 | -63.61% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 3.32 | -35.44% | 🇺🇸 USA |
 AstraZeneca AZN | 5.41 | 5.22% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 4.99 | -3.04% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | 1.19 | -76.82% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -83.2 | -1,717.61% | 🇺🇸 USA |